CRISPR Therapeutics (CRSP03) Stock Overview

A gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. More details

CRSP03 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 74% below our estimate of its fair value

Revenue is forecast to grow 64.83% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months compared to the TH market

Does not have meaningful revenue ($4M)

CRSP03 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

CRISPR Therapeutics AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for CRISPR Therapeutics
Historical stock prices
Current Share Price	US$3.40
52 Week High	US$3.88
52 Week Low	US$2.92
Beta	1.7
1 Month Change	-3.95%
3 Month Change	6.25%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-10.05%

Recent updates

Shareholder Returns

	CRSP03	TH Biotechs	TH Market
7D	-3.4%	0%	0%
1Y	n/a	0%	0%

Return vs Industry: Insufficient data to determine how CRSP03 performed against the TH Biotechs industry.

Return vs Market: Insufficient data to determine how CRSP03 performed against the TH Market.

Price Volatility

Is CRSP03's price volatile compared to industry and market?
CRSP03 volatility
CRSP03 Average Weekly Movement	8.5%
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in TH Market	0%
10% least volatile stocks in TH Market	0%

Stable Share Price: CRSP03's share price has been volatile over the past 3 months compared to the TH market.

Volatility Over Time: Insufficient data to determine CRSP03's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2013	393	Sam Kulkarni	www.crisprtx.com

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology.

CRISPR Therapeutics AG Fundamentals Summary

How do CRISPR Therapeutics's earnings and revenue compare to its market cap?
CRSP03 fundamental statistics
Market cap	฿163.34b
Earnings (TTM)	-฿18.70b
Revenue (TTM)	฿134.98m

1,210x

P/S Ratio

-8.7x

P/E Ratio

Is CRSP03 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CRSP03 income statement (TTM)
Revenue	US$4.10m
Cost of Revenue	US$482.82m
Gross Profit	-US$478.71m
Other Expenses	US$89.82m
Earnings	-US$568.53m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-5.89
Gross Margin	-11,667.39%
Net Profit Margin	-13,856.54%
Debt/Equity Ratio	32.3%

How did CRSP03 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/10 19:34
End of Day Share Price	2026/06/10 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CRISPR Therapeutics AG is covered by 40 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jack Allen	Baird
William Pickering	Bernstein
Alec Stranahan	BofA Global Research

CRISPR Therapeutics AGSET:CRSP03 Stock Report